Vanda Pharmaceuticals Inc. (VNDA) Analysts See $-0.09 EPS

April 17, 2018 - By Duane Lopez

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.26, from 1.43 in 2017Q3. It dropped, as 19 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 39.77 million shares or 2.28% more from 38.89 million shares in 2017Q3 were reported.
Dekabank Deutsche Girozentrale owns 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 11,100 shares. Wells Fargo Com Mn holds 174,222 shares or 0% of its portfolio. Texas-based Teacher Retirement Of Texas has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Cadence Cap Mgmt Ltd Limited Liability Company stated it has 0.11% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Moreover, Macquarie Gru Ltd has 0.06% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 33,000 are held by State Of Wisconsin Invest Board. Quantbot Technology L P stated it has 679 shares. Orbimed Advsrs Limited Liability Corporation holds 0.19% or 967,859 shares in its portfolio. Rice Hall James Limited Liability Corporation stated it has 28,245 shares or 0.02% of all its holdings. Prudential Financial has 0.01% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 704,009 shares. Tower Rech Limited Liability Company (Trc) invested in 0% or 2,011 shares. Manufacturers Life Insurance The invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Moreover, Great West Life Assurance Can has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 9,304 shares. Credit Suisse Ag, Switzerland-based fund reported 41,327 shares. Rothschild Asset Mngmt accumulated 1.37 million shares or 0.22% of the stock.

Since January 2, 2018, it had 0 buys, and 8 insider sales for $4.89 million activity. Gulino Richard L. had sold 3,660 shares worth $68,473 on Wednesday, February 28. Another trade for 60,966 shares valued at $1.14 million was made by Polymeropoulos Mihael Hristos on Wednesday, February 28. On Tuesday, January 2 Kelly James Patrick sold $140,494 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) or 9,155 shares.

Analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report $-0.09 EPS on May, 1.They anticipate $0.08 EPS change or 47.06 % from last quarter’s $-0.17 EPS. After having $-0.04 EPS previously, Vanda Pharmaceuticals Inc.’s analysts see 125.00 % EPS growth. The stock decreased 0.33% or $0.05 during the last trading session, reaching $15.05. About 269,841 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since April 17, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 4 analysts covering Vanda (NASDAQ:VNDA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda had 8 analyst reports since October 19, 2017 according to SRatingsIntel. Oppenheimer maintained the stock with “Buy” rating in Monday, January 8 report. On Wednesday, February 28 the stock rating was maintained by Seaport Global with “Buy”. The stock has “Buy” rating by Piper Jaffray on Thursday, October 19. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Monday, March 5. Oppenheimer has “Buy” rating and $27.0 target. The stock has “Buy” rating by Jefferies on Tuesday, February 13. The firm earned “Outperform” rating on Monday, October 30 by Oppenheimer. The rating was maintained by Oppenheimer on Sunday, November 12 with “Buy”.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $766.62 million. The company's marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.